RESUMO
The National Institute on Aging Interventions Testing Program (ITP) evaluates agents hypothesized to increase healthy lifespan in genetically heterogeneous mice. Each compound is tested in parallel at three sites, and all results are published. We report the effects of lifelong treatment of mice with four agents not previously tested: Protandim, fish oil, ursodeoxycholic acid (UDCA) and metformin - the latter with and without rapamycin, and two drugs previously examined: 17-α-estradiol and nordihydroguaiaretic acid (NDGA), at doses greater and less than used previously. 17-α-estradiol at a threefold higher dose robustly extended both median and maximal lifespan, but still only in males. The male-specific extension of median lifespan by NDGA was replicated at the original dose, and using doses threefold lower and higher. The effects of NDGA were dose dependent and male specific but without an effect on maximal lifespan. Protandim, a mixture of botanical extracts that activate Nrf2, extended median lifespan in males only. Metformin alone, at a dose of 0.1% in the diet, did not significantly extend lifespan. Metformin (0.1%) combined with rapamycin (14 ppm) robustly extended lifespan, suggestive of an added benefit, based on historical comparison with earlier studies of rapamycin given alone. The α-glucosidase inhibitor, acarbose, at a concentration previously tested (1000 ppm), significantly increased median longevity in males and 90th percentile lifespan in both sexes, even when treatment was started at 16 months. Neither fish oil nor UDCA extended lifespan. These results underscore the reproducibility of ITP longevity studies and illustrate the importance of identifying optimal doses in lifespan studies.
Assuntos
Antioxidantes/farmacologia , Estradiol/farmacologia , Inibidores de Glicosídeo Hidrolases/farmacologia , Longevidade/efeitos dos fármacos , Fator 2 Relacionado a NF-E2/metabolismo , alfa-Glucosidases/metabolismo , Acarbose/farmacologia , Animais , Medicamentos de Ervas Chinesas/farmacologia , Óleos de Peixe/farmacologia , Força da Mão , Masculino , Masoprocol/farmacologia , Metformina/farmacologia , Camundongos , Teste de Desempenho do Rota-Rod , Sirolimo/farmacologia , Análise de Sobrevida , Ácido Ursodesoxicólico/farmacologiaRESUMO
THE NIA INTERVENTIONS TESTING PROGRAM ENCOURAGES PARTICIPATION BY THE RESEARCH COMMUNITY THOUGH ITS ANNUAL CALL-FOR-PROPOSALS. THIS SHORT TAKE SERVES AS A BRIEF INTRODUCTION TO THE PROGRAM AND ANNOUNCEMENT FOR THE NEXT PROPOSAL RECEIPT DATE.
RESUMO
Four agents--acarbose (ACA), 17-α-estradiol (EST), nordihydroguaiaretic acid (NDGA), and methylene blue (MB)--were evaluated for lifespan effects in genetically heterogeneous mice tested at three sites. Acarbose increased male median lifespan by 22% (P < 0.0001), but increased female median lifespan by only 5% (P = 0.01). This sexual dimorphism in ACA lifespan effect could not be explained by differences in effects on weight. Maximum lifespan (90th percentile) increased 11% (P < 0.001) in males and 9% (P = 0.001) in females. EST increased male median lifespan by 12% (P = 0.002), but did not lead to a significant effect on maximum lifespan. The benefits of EST were much stronger at one test site than at the other two and were not explained by effects on body weight. EST did not alter female lifespan. NDGA increased male median lifespan by 8-10% at three different doses, with P-values ranging from 0.04 to 0.005. Females did not show a lifespan benefit from NDGA, even at a dose that produced blood levels similar to those in males, which did show a strong lifespan benefit. MB did not alter median lifespan of males or females, but did produce a small, statistically significant (6%, P = 0.004) increase in female maximum lifespan. These results provide new pharmacological models for exploring processes that regulate the timing of aging and late-life diseases, and in particular for testing hypotheses about sexual dimorphism in aging and health.
Assuntos
Acarbose/farmacologia , Estradiol/farmacologia , Longevidade/efeitos dos fármacos , Masoprocol/farmacologia , Animais , Biomarcadores/metabolismo , Peso Corporal , Feminino , Masculino , Azul de Metileno , Camundongos , Análise de SobrevidaRESUMO
Rapamycin, an inhibitor of mTOR kinase, increased median lifespan of genetically heterogeneous mice by 23% (males) to 26% (females) when tested at a dose threefold higher than that used in our previous studies; maximal longevity was also increased in both sexes. Rapamycin increased lifespan more in females than in males at each dose evaluated, perhaps reflecting sexual dimorphism in blood levels of this drug. Some of the endocrine and metabolic changes seen in diet-restricted mice are not seen in mice exposed to rapamycin, and the pattern of expression of hepatic genes involved in xenobiotic metabolism is also quite distinct in rapamycin-treated and diet-restricted mice, suggesting that these two interventions for extending mouse lifespan differ in many respects.
Assuntos
Longevidade/efeitos dos fármacos , Sirolimo/farmacologia , Fatores Etários , Animais , Restrição Calórica , Relação Dose-Resposta a Droga , Feminino , Masculino , Camundongos , Fatores Sexuais , Serina-Treonina Quinases TOR/antagonistas & inibidores , Serina-Treonina Quinases TOR/metabolismoRESUMO
The National Institute on Aging Interventions Testing Program (ITP) was established to evaluate agents that are hypothesized to increase life span and/or health span in genetically heterogeneous mice. Each compound is tested in parallel at three test sites. It is the goal of the ITP to publish all results, negative or positive. We report here on the results of lifelong treatment of mice, beginning at 4 months of age, with each of five agents, that is, green tea extract (GTE), curcumin, oxaloacetic acid, medium-chain triglyceride oil, and resveratrol, on the life span of genetically heterogeneous mice. Each agent was administered beginning at 4 months of age. None of these five agents had a statistically significant effect on life span of male or female mice, by log-rank test, at the concentrations tested, although a secondary analysis suggested that GTE might diminish the risk of midlife deaths in females only.
Assuntos
Curcumina/farmacologia , Longevidade/efeitos dos fármacos , Ácido Oxaloacético/farmacologia , Estilbenos/farmacologia , Chá , Triglicerídeos/farmacologia , Fatores Etários , Envelhecimento/efeitos dos fármacos , Envelhecimento/patologia , Envelhecimento/fisiologia , Animais , Peso Corporal/efeitos dos fármacos , Avaliação Pré-Clínica de Medicamentos , Feminino , Longevidade/genética , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C3H , Camundongos Endogâmicos C57BL , Camundongos Endogâmicos DBA , Modelos Animais , Atividade Motora/efeitos dos fármacos , Gravidez , Resveratrol , Caracteres Sexuais , Triglicerídeos/químicaRESUMO
Rapamycin was administered in food to genetically heterogeneous mice from the age of 9 months and produced significant increases in life span, including maximum life span, at each of three test sites. Median survival was extended by an average of 10% in males and 18% in females. Rapamycin attenuated age-associated decline in spontaneous activity in males but not in females. Causes of death were similar in control and rapamycin-treated mice. Resveratrol (at 300 and 1200 ppm food) and simvastatin (12 and 120 ppm) did not have significant effects on survival in male or female mice. Further evaluation of rapamycin's effects on mice is likely to help delineate the role of the mammalian target of rapamycin complexes in the regulation of aging rate and age-dependent diseases and may help to guide a search for drugs that retard some or all of the diseases of aging.
Assuntos
Longevidade/efeitos dos fármacos , Sinvastatina/administração & dosagem , Sirolimo/administração & dosagem , Estilbenos/administração & dosagem , Envelhecimento/efeitos dos fármacos , Envelhecimento/genética , Animais , Feminino , Heterogeneidade Genética , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C3H , Camundongos Endogâmicos C57BL , Camundongos Endogâmicos DBA , ResveratrolRESUMO
Inhibition of the TOR signalling pathway by genetic or pharmacological intervention extends lifespan in invertebrates, including yeast, nematodes and fruitflies; however, whether inhibition of mTOR signalling can extend lifespan in a mammalian species was unknown. Here we report that rapamycin, an inhibitor of the mTOR pathway, extends median and maximal lifespan of both male and female mice when fed beginning at 600 days of age. On the basis of age at 90% mortality, rapamycin led to an increase of 14% for females and 9% for males. The effect was seen at three independent test sites in genetically heterogeneous mice, chosen to avoid genotype-specific effects on disease susceptibility. Disease patterns of rapamycin-treated mice did not differ from those of control mice. In a separate study, rapamycin fed to mice beginning at 270 days of age also increased survival in both males and females, based on an interim analysis conducted near the median survival point. Rapamycin may extend lifespan by postponing death from cancer, by retarding mechanisms of ageing, or both. To our knowledge, these are the first results to demonstrate a role for mTOR signalling in the regulation of mammalian lifespan, as well as pharmacological extension of lifespan in both genders. These findings have implications for further development of interventions targeting mTOR for the treatment and prevention of age-related diseases.
Assuntos
Envelhecimento/efeitos dos fármacos , Envelhecimento/fisiologia , Longevidade/efeitos dos fármacos , Longevidade/genética , Sirolimo/administração & dosagem , Sirolimo/farmacologia , Administração Oral , Envelhecimento/genética , Animais , Proteínas de Transporte/antagonistas & inibidores , Proteínas de Transporte/metabolismo , Dieta , Suscetibilidade a Doenças , Feminino , Longevidade/fisiologia , Masculino , Camundongos , Fosfotransferases (Aceptor do Grupo Álcool)/antagonistas & inibidores , Fosfotransferases (Aceptor do Grupo Álcool)/metabolismo , Organismos Livres de Patógenos Específicos , Análise de Sobrevida , Serina-Treonina Quinases TOR , Fatores de TempoRESUMO
The National Institute on Aging's Interventions Testing Program was established to evaluate agents that are purported to increase lifespan and delay the appearance of age-related disease in genetically heterogeneous mice. Up to five compounds are added to the study each year and each compound is tested at three test sites (The Jackson Laboratory, University of Michigan, and University of Texas Health Science Center at San Antonio). Mice in the first cohort were exposed to one of four agents: aspirin, nitroflurbiprofen, 4-OH-alpha-phenyl-N-tert-butyl nitrone, or nordihydroguaiaretic acid (NDGA). Sample size was sufficient to detect a 10% difference in lifespan in either sex,with 80% power, using data from two of the three sites. Pooling data from all three sites, a log-rank test showed that both NDGA (p=0.0006) and aspirin (p=0.01) led to increased lifespan of male mice. Comparison of the proportion of live mice at the age of 90% mortality was used as a surrogate for measurement of maximum lifespan;neither NDGA (p=0.12) nor aspirin (p=0.16) had a significant effect in this test. Measures of blood levels of NDGA or aspirin and its salicylic acid metabolite suggest that the observed lack of effects of NDGA or aspirin on life span in females could be related to gender differences in drug disposition or metabolism. Further studies are warranted to find whether NDGA or aspirin, over a range of doses,might prove to postpone death and various age-related outcomes reproducibly in mice.
Assuntos
Aspirina/administração & dosagem , Heterogeneidade Genética/efeitos dos fármacos , Longevidade/efeitos dos fármacos , Longevidade/genética , Masoprocol/administração & dosagem , Animais , Aspirina/sangue , Óxidos N-Cíclicos/administração & dosagem , Inibidores de Ciclo-Oxigenase/administração & dosagem , Feminino , Flurbiprofeno/administração & dosagem , Flurbiprofeno/análogos & derivados , Sequestradores de Radicais Livres/administração & dosagem , Inibidores de Lipoxigenase/administração & dosagem , Masculino , Masoprocol/sangue , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C3H , Camundongos Endogâmicos C57BL , Camundongos Endogâmicos DBA , Distribuição Aleatória , Caracteres Sexuais , Análise de SobrevidaRESUMO
The National Institute on Aging's Interventions Testing Program (ITP) has developed a plan to evaluate agents that are considered plausible candidates for delaying rates of aging. Key features include: (i) use of genetically heterogeneous mice (a standardized four-way cross), (ii) replication at three test sites (the Jackson Laboratory, TJL; University of Michigan, UM; and University of Texas, UT), (iii) sufficient statistical power to detect 10% changes in lifespan, (iv) tests for age-dependent changes in T cell subsets and physical activity, and (v) an annual solicitation for collaborators who wish to suggest new interventions for evaluation. Mice in the first cohort were exposed to one of four agents: aspirin, nitroflurbiprofen (NFP), 4-OH-alpha-phenyl-N-tert-butyl nitrone (4-OH-PBN), or nordihydroguiaretic acid (NDGA). An interim analysis was conducted using survival data available on the date at which at least 50% of the male control mice had died at each test site. Survival of control males was significantly higher, at the interim time-point, at UM than at UT or TJL; all three sites had similar survival of control females. Males in the NDGA group had significantly improved survival (P = 0.0004), with significant effects noted at TJL (P < 0.01) and UT (P < 0.04). None of the other agents altered survival, although there was a suggestion (P = 0.07) of a beneficial effect of aspirin in males. More data will be needed to determine if any of these compounds can extend maximal lifespan, but the current data show that NDGA reduces early life mortality risks in genetically heterogeneous mice at multiple test sites.
Assuntos
Envelhecimento/efeitos dos fármacos , Aspirina/farmacologia , Óxidos N-Cíclicos/farmacologia , Flurbiprofeno/análogos & derivados , Masoprocol/farmacologia , Animais , Anti-Inflamatórios não Esteroides/farmacologia , Antioxidantes/farmacologia , Avaliação Pré-Clínica de Medicamentos , Feminino , Flurbiprofeno/farmacologia , Masculino , Camundongos , Projetos de Pesquisa , Análise de SobrevidaRESUMO
Animal models have paved the way for the vast majority of advances in biomedical research. Studies on aged animals are essential for understanding the processes inherent in normal aging and the progression of age-related diseases. Animal models are used to identify physiological changes with age, to identify the genetic basis of normal aging and age-associated disease and degeneration, and to test potential therapeutic interventions. This chapter will focus on rodent models and will summarize important considerations for the use of animals in aging research in general and in modeling geriatric epilepsy.
Assuntos
Pesquisa Biomédica , Modelos Animais de Doenças , Epilepsia , Geriatria , Animais , Humanos , RoedoresRESUMO
The preponderance of our understanding of the biological changes that occur with aging has come from studies using rodents. Rodents are a valuable model for biogerontology research because of similarities to humans in the physiology and cell biology of aging. There are, however, many differences between rodents and humans, so application of findings in rodents to human aging requires the use of a model that is closer to humans at the genetic and physiological level. In aging research, the macaque has filled this need. There are many challenges associated with using nonhuman primates in aging research, not the least of which are the limited availability of aged monkeys and the cost of using them. To facilitate this research, the National Institute on Aging has developed several resources to assist investigators and promote the use of the nonhuman primate model in aging research.
Assuntos
Pesquisa Biomédica , Geriatria , Modelos Animais , National Institutes of Health (U.S.) , Animais , Haplorrinos , Roedores , Estados UnidosRESUMO
The rodent is a particularly valuable model with which to test therapeutic interventions for aging, as rodent physiology is close enough to human physiology to give the findings relevance for human aging, and it is small enough to allow for use of statistically robust sample sizes. There are many rodent models to choose from, with advantages and disadvantages to each. The choice of model system, as well as other experimental design decisions such as diet and housing, is extremely important for the success of lifespan studies. These issues are discussed in this review of the use of the rodent model. The National Institute on Aging (NIA) Interventions Testing Program, which has grappled with all of these issues, is described.
Assuntos
Longevidade/efeitos dos fármacos , Modelos Animais , Farmacologia Clínica/métodos , Roedores/fisiologia , Animais , Dieta , Abrigo para AnimaisRESUMO
The use of DNA microarrays allows rapid, large-scale analyses of changes in gene expression. This article introduces the National Institute on Aging Microarray Facility, developed to provide DNA microarrays to the biogerontology research community and to promote the use of this new technology.